Ibogaine Clinical Trials Recruiting in the United States: A 2026 Guide to ClinicalTrials.gov Listings

If you have searched ClinicalTrials.gov for ibogaine trials recruiting in the United States, you already know the frustration: listings are sparse, statuses change without warning, and the terminology — "recruiting," "active, not recruiting," "completed" — can obscure whether you actually have a path to enrollment. This guide explains how to read the ibogaine listings on ClinicalTrials.gov in 2026, what the current research landscape looks like, and what options exist for people who cannot wait for a U.S. trial slot.

For a continuously updated overview of the studies, sponsors, and state-level initiatives shaping this field, see the ibogaine research hub, which tracks trial activity alongside published outcomes.

Why Ibogaine Trials Are So Hard to Find on ClinicalTrials.gov

Ibogaine remains a Schedule I substance in the United States. That single fact explains most of what you see — and don't see — when you search the federal registry. Schedule I status means every U.S. trial requires an FDA Investigational New Drug (IND) application, DEA registration for the study site, and institutional review board approval for a compound with known cardiac considerations. Each layer adds months or years before a study ever posts a "Recruiting" status.

The result: at any given time, only a handful of ibogaine or ibogaine-analog studies appear for U.S. locations, and several of the most-cited entries are observational rather than interventional. When people search "clinicaltrials.gov ibogaine recruiting united states," what they usually find is a mix of:

• Completed studies whose results are informing the next generation of trials
• Observational and survey-based research that follows people who received ibogaine treatment abroad
• Analog trials studying non-hallucinogenic derivatives of ibogaine rather than ibogaine itself
• Early-phase safety studies with narrow inclusion criteria and small enrollment targets

Understanding which category a listing falls into is the difference between a realistic enrollment path and a dead end.

NCT05029401: The Oral Ibogaine Opioid Withdrawal Study, Explained

One listing dominates search interest: NCT05029401, a study of oral ibogaine for opioid withdrawal. Its status on ClinicalTrials.gov now reads completed, which surprises many people who bookmarked it while it was recruiting.

"Completed" does not mean the research failed — it means enrollment and follow-up finished and the data have moved into analysis and publication. Completed studies like this one matter for three reasons:

1. They establish safety protocols. Dosing schedules, cardiac monitoring standards, and screening criteria refined in completed trials become the template for the next round of studies — and for responsible clinics operating outside the U.S. today.
2. They generate the evidence regulators need. FDA decisions about future ibogaine INDs draw directly on completed-trial safety data.
3. They signal where sponsors will go next. A completed Phase 1/2 study typically precedes a larger Phase 2b or Phase 3 trial, often at additional sites.

If NCT05029401 was the study you hoped to join, the practical move is to set a ClinicalTrials.gov saved-search alert for "ibogaine" filtered to United States locations, and to watch the sponsor's pipeline for follow-on trials. Our team summarizes these developments in plain language on the ibogaine research hub as they post.

Where U.S. Ibogaine Research Is Actually Happening in 2026

State-Funded Research Programs

The most significant U.S. ibogaine development is not a single trial — it is state legislation. Texas approved a landmark $50 million initiative to fund ibogaine clinical research, a move designed to fast-track FDA-sanctioned trials for veterans and people with opioid use disorder. The details of how Texas committed $50 million to ibogaine research matter because state funding removes the biggest bottleneck in psychedelic research: money for Schedule I compliance infrastructure.

Kentucky pursued a similar path earlier, proposing opioid-settlement funds for ibogaine trials. While that specific proposal stalled, the policy blueprint it created continues to influence other states — background we cover in our summary of ibogaine research in Kentucky.

Searches for trials recruiting in specific states — Wisconsin among them — reflect this state-by-state momentum. As of early 2026, no ibogaine trial lists a Wisconsin site, but state-funded programs in Texas are expected to open multi-site recruitment, and geography will broaden as sponsors add locations.

Academic Observational Studies

Stanford's observational study of ibogaine treatment in special operations veterans produced some of the most striking data in the field: an 88% reduction in PTSD symptoms alongside major improvements in depression, anxiety, and cognitive function after traumatic brain injury. Because participants received treatment at a clinic in Mexico, the study did not require U.S. Schedule I trial infrastructure — which is exactly why it could move fast. The full findings are summarized in our breakdown of Stanford's groundbreaking ibogaine study.

Observational designs like Stanford's are now recruiting-adjacent opportunities: researchers periodically enroll people who are already planning treatment abroad. If you are considering treatment, asking whether any academic follow-up study is enrolling is worth five minutes of your time — your outcomes data can advance the field.

Analog and Derivative Trials

Several biotech sponsors are advancing ibogaine analogs engineered to reduce cardiac risk or remove hallucinogenic effects. These trials do appear on ClinicalTrials.gov with U.S. recruiting sites, but enrolling in an analog trial is not the same as receiving ibogaine. Read the intervention field carefully — "ibogaine" in a study title sometimes refers to a derivative molecule.

How to Search ClinicalTrials.gov Effectively for Ibogaine Studies

A few practical techniques save hours:

• Search "ibogaine" AND "noribogaine" separately. Noribogaine is ibogaine's active metabolite and some studies register under that term.
• Filter by status, not just location. Select "Recruiting" and "Not yet recruiting" — the latter catches trials weeks before they open.
• Set email alerts. ClinicalTrials.gov lets you save searches and receive notifications when statuses change. Given how quickly small trials fill, this is the single highest-value step.
• Check the sponsor's own site. Sponsors often pre-screen interest lists before the registry status flips to "Recruiting."
• Verify eligibility criteria early. Most ibogaine trials exclude people with QT-interval prolongation, certain psychiatric histories, and active use of interacting medications, including many SSRIs.

What If You Don't Qualify — or Can't Wait?

This is the question behind most trial searches. U.S. ibogaine trials, when they exist, enroll dozens of people, while hundreds of thousands are seeking alternatives for opioid dependence, PTSD, and treatment-resistant depression right now.

Licensed medical treatment outside the United States is the established path. Mexico permits physician-supervised ibogaine treatment, and the safety protocols refined by clinical research — continuous cardiac monitoring, pre-treatment EKG and bloodwork, medically supervised medication tapering — are precisely what separates a legitimate medical program from an unregulated provider. Our guide to choosing an ibogaine treatment clinic walks through the screening standards that mirror clinical-trial safety requirements.

Anyone weighing this route should also understand the mechanism they are signing up for. Ibogaine's effects on opioid receptors, neurotrophic factors, and addiction circuitry are the reason researchers keep returning to this molecule despite the regulatory hurdles — a subject we cover in depth in how ibogaine works.

The legal picture matters too. Ibogaine remains illegal to administer in the U.S. outside of an FDA-sanctioned trial, and understanding the boundaries protects you from providers operating in gray zones. See the complete ibogaine legal guide for 2026 for the state-by-state and international breakdown.

Frequently Asked Questions

Are any ibogaine trials currently recruiting in the United States? Listings change monthly. As of early 2026, U.S.-based interventional ibogaine trials are limited, with state-funded programs in Texas expected to open new recruitment. Analog trials and observational studies recruit more frequently. Set a ClinicalTrials.gov alert for the most current picture.

What happened to NCT05029401? The oral ibogaine opioid withdrawal study completed enrollment and follow-up. Its status is "Completed," and its data are informing successor trials.

Why does a completed trial still matter to me? Completed trials define the safety standards — cardiac screening, dosing protocols, medication washout periods — used both by future trials and by reputable international clinics today.

Can I get ibogaine treatment legally without joining a trial? Not in the United States. Physician-supervised treatment is legal in Mexico and select other countries, which is where the majority of documented modern treatment outcomes — including Stanford's veteran cohort — originate.

The Bottom Line

The gap between research interest and trial availability defines ibogaine in 2026: the science is accelerating, state funding is arriving, and completed studies like NCT05029401 are building the evidence base — but recruiting slots in the U.S. remain scarce. Track the registry with saved alerts, follow state-funded programs as they open sites, and rely on the MindScape Retreat ibogaine research hub for plain-language updates on which studies are recruiting, which have completed, and what their results mean for treatment access.